Venturis Therapeutics

Executive Summary

Venturis Therapeutics is a preclinical biopharmaceutical company developing protein-based drug candidates for chronic ischemic diseases and wound healing. Founded in 2021 and headquartered in Cambridge, MA, the company focuses on severe coronary heart disease, peripheral artery disease, and diabetic wounds. Its proprietary platform leverages novel protein therapeutics to address significant unmet medical needs in vascular repair and tissue regeneration. While still in early-stage development, Venturis aims to advance its lead candidates toward IND-enabling studies, with a strong emphasis on addressing large markets such as diabetic foot ulcers and critical limb ischemia. The company operates in a competitive landscape with several players targeting similar indications, but its differentiated protein approach may offer advantages in safety and efficacy. Key risks include the inherent uncertainty of preclinical development, limited funding visibility (as a private company with no disclosed total raised), and the need for robust clinical validation. Nevertheless, the company's focus on high-morbidity diseases positions it for potential partnering or licensing opportunities if preclinical data are positive. The upcoming milestones will be critical for assessing its scientific and commercial viability.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data for lead candidate in diabetic wound model60% success
• Q2 2027IND filing for lead candidate targeting peripheral artery disease40% success